Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.
13. desember 2016 oppdatert av: Erik Andersson, Karolinska Institutet
The purpose of this study is to examine if an internet-based exposure therapy is effective in reducing Fibromyalgia symptoms and impact amongst patients with Fibromyalgia.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Trial Objectives: Primary objective is to investigate whether an Internet-based exposure therapy can effectively reduce the degree of Fibromyalgia symptoms and impact. Secondary objectives are to 1) investigate the treatment's ability to reduce degree of a) quality of life b) function c) insomnia and fatigue d) pain-related fear and negative thoughts e) depression and anxiety, cost-effectiveness of this treatment; and 2) to study if any variables could moderate/mediate the treatment outcome, such as a) degree of covert avoidance, b) degree of reactivity to inner sensations
Trial Design: Randomized controlled trial with waitlist control, who also will receive treatment after the first group has finished.
Duration: Ten weeks
Primary Endpoint: Change in Fibromyalgia symptoms and impact from baseline to Week 10. Long term follow-up is also investigated (potential changes from post-treatment to 6- and 12 months after treatment completion)
Efficacy Parameters: the Fibromyalgia Impact Questionnaire (FIQ)
Description of Trial Subjects: Patients > 18 years old, Fibromyalgia diagnosis, residing in Sweden.
Number of Subjects: 140
Sample size estimation: Sample size is based on a estimated effect size (measured by Cohen's d) of 0.5, based on a power of 0.8 and with room for a 10 % dropout rate.
Recruitment: Self-referral. Advertising will be made through national newspaper, social media and on patient organisations' websites.
Safety parameters: Participants will have the opportunity to report any adverse events during treatment at posttreatment and follow-up measurements.
Data collection: Data will be collected electronically via the treatment platform.
Plan for missing data: Last-observation carried forward (LOCF).
Main statistical analysis: Hierarchical linear mixed modelling.
Studietype
Intervensjonell
Registrering (Faktiske)
140
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Stockholm
-
Solna, Stockholm, Sverige, 17177
- Karolinska Institutet
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 100 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Fibromyalgia diagnosis
- Swedish resident
- Internet connection before, under and after treatment
- Willing to refrain from other concurrent psychological treatment during the study
- Agreement to keep psychotrophic medication constant during the study
Exclusion Criteria:
- Severe depression (≥30 points on Montgomery Åsberg Depression Rating Scale - Self Rated (MADRS-S) or risk of suicide (≥4 points on the suicide item on MADRS-S)
- Ongoing alcohol or substance abuse
- Psychosis
- Other severe illness that require immediate treatment and/or was considered the participants primary concern other than FM, or bodily condition that makes treatment unfeasible (such as late pregnancy; >29 weeks gestation
- Illiteracy or poor skills in Swedish language
- Insufficient computer or language skills to manage a text-based treatment.
- Other concurrent psychological treatment
- Recent changes in psychotrophic medication (<6 weeks prior to randomization)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Internet-based exposure therapy
The experimental group will go through active internet-based treatment which is delivered on a safe internet platform.
Treatment is divided into eight modules, each containing homework assignments.
Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 48 hours.
|
The treatment is a 10 week long cognitive behavior therapy.
It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
|
|
Ingen inngripen: Waitlist
Waitlist control, i.e. no active active intervention during waiting list period.
Will be offered treatment when the first group has finished (i.e.
week 10).
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in the Fibromyalgia Impact Questionnaire (FIQ)
Tidsramme: Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
Change in Fibromyalgia symptoms and impact from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, Long term follow-up at 6- and 12-months after treatment has ended]
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Insomnia Severity Index (ISI)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in sleep disturbances from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Fatigue Severity Scale (FSS)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in fatigue from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
WHO Disability Assessment Schedule 2.0 (WHODAS 2)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of function from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Brunnsviken Brief Quality of Life Inventory (BBQ)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in quality of life from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
The Psychological Inflexibility in Pain Scale (PIPS)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in covert avoidance from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Pain Reactivity Scale (PRS)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in pain-related fear and negative thoughts from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of depression from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Generalised Anxiety Disorder 7-item scale (GAD-7)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in level of anxiety from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Subscale "reactivity to inner experiences" from Five Facets of Mindfulness Questionnaire (FFMQ)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in reactivity to inner experiences from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P)
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-care costs and sick-leave from baseline to Week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
|
EQ5D
Tidsramme: Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Change in health-related quality of life from baseline to week 10, and at 6- and 12 months after treatment has ended.
|
Week 0, week 10, follow-up at 6- and 12-months after treatment has ended
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Item 9 from Montgomery Asberg Depression Rating Scale (MADRS-S)
Tidsramme: Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
Possible presence of suicidal thoughts or ideation during treatment
|
Week 1, week 2, week 3, week 4, week 5, week 6, week, 7, week 8, week 9
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. desember 2015
Primær fullføring (Faktiske)
1. juli 2016
Studiet fullført (Faktiske)
1. juli 2016
Datoer for studieregistrering
Først innsendt
17. desember 2015
Først innsendt som oppfylte QC-kriteriene
19. desember 2015
Først lagt ut (Anslag)
23. desember 2015
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
14. desember 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
13. desember 2016
Sist bekreftet
1. desember 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- EPN 2015/1528-31/1
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
UBESLUTTE
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .